Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04530110
Previous Study | Return to List | Next Study

A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04530110
Recruitment Status : Enrolling by invitation
First Posted : August 28, 2020
Last Update Posted : November 17, 2020
Sponsor:
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Teva Branded Pharmaceutical Products R&D, Inc. )

Brief Summary:

The primary objective of the study is to evaluate the long-term safety and tolerability of subcutaneous fremanezumab in the preventive treatment of migraine in pediatric participants 6 to 17 years of age (inclusive at enrollment in the pivotal study).

Secondary objectives are to evaluate the efficacy of subcutaneous fremanezumab in pediatric participants with migraine and to evaluate the immunogenicity of fremanezumab and the impact of ADAs on clinical outcomes in pediatric participants exposed to fremanezumab.

The total duration of the study is planned to be up to 60 months.


Condition or disease Intervention/treatment Phase
Migraine Drug: Fremanezumab Phase 3

Detailed Description:

The study population will be composed of 3 subgroups of participants as follows:

  • Participants rolling over from the pivotal Phase 3 pediatric efficacy studies (Studies TV48125-CNS-30082 and TV48125-CNS-30083)
  • Participants rolling over from the Phase 1 pediatric pharmacokinetic study (Study TV48125-CNS-10141)
  • Participants rolling over from the pivotal Phase 3 pediatric efficacy studies (Studies TV48125-CNS-30082 and TV48125-CNS-30083) for safety follow-up and antidrug antibody (ADA) evaluation only

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 550 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age
Actual Study Start Date : September 16, 2020
Estimated Primary Completion Date : May 16, 2023
Estimated Study Completion Date : May 24, 2024

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Migraine
MedlinePlus related topics: Migraine

Arm Intervention/treatment
Experimental: Fremanezumab
The dose of Fremanezumab to be administered will be confirmed or adjusted, as appropriate, based on the participant's weight every 3 months.
Drug: Fremanezumab

Participants weighing ≥ threshold will receive Dose A subcutaneously monthly.

Participants weighing < threshold will receive Dose B subcutaneously monthly.

Subcutaneously monthly, confirmed or adjusted, as appropriate, based on the participant's weight every 3 months.





Primary Outcome Measures :
  1. Incidence of adverse events [ Time Frame: Day 1 - Day 393 ]
    including local injection site reaction/pain

  2. Incidence of participants with clinically significant changes in laboratory values [ Time Frame: Day 1 - Day 253 ]
  3. Incidence of abnormal standard 12-lead electrocardiogram (ECG) findings [ Time Frame: Day 1 - Day 253 ]
  4. Incidence of abnormal vital signs [ Time Frame: Day 1 - Day 253 ]
    (systolic and diastolic blood pressure, pulse, temperature, and respiratory rate), height, and weight measurements

  5. Incidence of abnormal physical examination findings [ Time Frame: Day 1- Day 393 ]
  6. Yes/No suicidality ideation [ Time Frame: Day 1 - Day 393 ]
    Columbia-Suicide Severity Rating Scale (C-SSRS) The C-SSRS is an assessment tool that evaluates suicidal ideation and behavior. Scale range: Yes or No response to 10 questions, with minimum to maximum range of 0 to 10. Lower score represents better outcomes.


Secondary Outcome Measures :
  1. Mean change in the number of headache days of at least moderate severity [ Time Frame: Day 1 - Day 253 ]
  2. Mean change in the number of migraine days [ Time Frame: Day 1 - Day 253 ]
  3. Proportion of participants reaching at least 50% reduction in the number of migraine days [ Time Frame: Day 1 - Day 253 ]
  4. Proportion of participants reaching at least 50% reduction in the number of headache days of at least moderate severity [ Time Frame: Day 1 - Day 253 ]
  5. Mean change in the number of days of use of any acute headache medications [ Time Frame: Day 1 - Day 253 ]
  6. Mean change in the PedMIDAS questionnaire score [ Time Frame: Day 1 - Day 393 ]
    The Pediatric Migraine Disability Assessment (PedMIDAS) is used to assess migraine disability across multiple domains of functioning including school, home, social, and recreational. The measure consists of 6 items measuring the number of days in which activities were missed as a result of headache/migraine. The measure yields a total score by summing items. Total scores correspond to one of four "disability grades:" 0-10 = little to no disability, 11-30 = mild disability, 31-50 = moderate disability, and >50 = severe disability.

  7. Proportion of participants developing antidrug antibodies (ADAs) throughout the study [ Time Frame: Day 1 - Day 393 ]
    The impact of ADAs on safety and efficacy will be analyzed if the number of ADA-positive participants allows.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Inclusion Criteria for Participants Rolling Over from the Pivotal Efficacy Studies (TV48125-CNS-30082 or TV48125-CNS-30083):

  • Participants have completed the pivotal efficacy study and, in the opinion of the Investigator or the Sponsor, are able to complete the study in a safe and compliant way.
  • Participants may continue with a stable dose/regimen of the preventive medication they were taking during the pivotal efficacy studies.
  • The participant continues to meet appropriate criteria carried forward from the pivotal efficacy study/
  • The participant has received all recommended age-appropriate vaccines according to local standard of care and schedule.
  • The participant weighs at least 17.0 kg on the day of study enrollment.

NOTE: Additional criteria apply; please contact the investigator for more information.

Inclusion Criteria for Participants Rolling Over from the Phase 1 Pediatric Pharmacokinetic Study (Study TV48125-CNS-10141):

  • The participant/caregiver has demonstrated compliance with the electronic headache diary during the 28-day baseline period by entry of headache data on a minimum of 21 out of 28 days (approximately 75% diary compliance).
  • The participant has received all recommended age-appropriate vaccines according to local standard of care and schedule.
  • The participant weighs at least 17.0 kg on the day of study enrollment.
  • The participant has a body mass index ranging from the 5th to the 95th percentile, inclusive, on the day of study enrollment.
  • Not using preventive medications or using no more than 1 preventive medication for migraine or other medical condition, as long as the dose and regimen have been stable for at least 2 months prior to screening (visit 1).

NOTE: Additional criteria apply; please contact the investigator for more information.

Inclusion Criteria for Participants Rolling Over from the Pivotal Efficacy Studies (TV48125-CNS-30082 and TV48125-CNS-30083) for Safety and antidrug antibody (ADA) Assessment Only:

• Participants may be included in this study if they sign and date the informed consent document or upon consent of a parent or guardian, if the participant is younger than the age of consent, accompanied by assent of the participant.

Exclusion Criteria:

Exclusion Criteria for Participants Rolling Over from the Pivotal Efficacy Studies (TV48125-CNS-30082 or TV48125-CNS-30083):

  • In the judgment of the investigator, the participant has a clinically significant abnormal finding on study entry, including hematology, blood chemistry, coagulation tests, or urinalysis values/findings (abnormal tests may be repeated for confirmation).
  • The participant has a current history of a clinically significant psychiatric condition, any prior history of a suicide attempt, or a history of suicidal ideation with a specific plan within the past 2 years, at the discretion of the investigator.
  • The participant has an ongoing infection or a known history of human immunodeficiency virus infection, tuberculosis, Lyme disease, or chronic hepatitis B or C, or a known active infection of coronavirus disease 2019 (COVID-19).
  • The participant has a history of hypersensitivity reactions to injected proteins, including mAbs, or a history of Stevens-Johnson Syndrome or toxic epidermal necrolysis syndrome, or the participant is concomitantly using lamotrigine.
  • The participant received a live attenuated vaccine (eg, intranasal flu vaccine, and measles, mumps, and rubella vaccine) within the 12-week period prior to screening. Note: If a medical need arises during the study, the participant may receive a live attenuated vaccine.
  • The participant is pregnant, nursing, or taking a combined estrogen and progestogen hormonal contraceptive.
  • In the judgment of the investigator, the participant has an abnormal finding on the baseline 12-lead ECG considered clinically significant.

NOTE: Additional criteria apply; please contact the investigator for more information.

Exclusion Criteria for Participants Rolling Over from the Phase 1 Pharmacokinetic Study (TV48125-CNS-10141):

  • The participant has any clinically significant cardiovascular (including congenital cardiac anomalies or thromboembolic events), endocrine, gastrointestinal, genitourinary, hematologic, hepatic, immunologic, neurologic, ophthalmic, pulmonary, renal disease, or complications of an infection, at the discretion of the investigator.
  • The participant has a current history of a clinically significant psychiatric condition, any prior history of a suicide attempt, or a history of suicidal ideation with a specific plan within the past 2 years, at the discretion of the investigator.
  • The participant has an ongoing infection or a known history of human immunodeficiency virus infection, tuberculosis, Lyme disease, or chronic hepatitis B or C, or a known active infection of coronavirus disease 2019 (COVID-19).
  • The participant has a history of hypersensitivity reactions to injected proteins, including mAbs, or a history of Stevens-Johnson Syndrome or toxic epidermal necrolysis syndrome, or the participant is concomitantly using lamotrigine.
  • The participant received a live attenuated vaccine (eg, intranasal flu vaccine, and measles, mumps, and rubella vaccine) within the 12-week period prior to screening. Note: If a medical need arises during the study, the participant may receive a live attenuated vaccine.
  • The participant is pregnant, nursing, or taking a combined estrogen and progestogen hormonal contraceptive.
  • In the judgment of the investigator, the participant has an abnormal finding on the baseline 12-lead ECG considered clinically significant.

NOTE: Additional criteria apply; please contact the investigator for more information.

Exclusion Criteria for Participants Rolling Over from the Pivotal Efficacy Studies (TV48125-CNS-30082 and TV48125-CNS-30083) for Safety and antidrug antibody (ADA) Assessment Only: Not Applicable


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04530110


Locations
Layout table for location information
United States, Florida
Teva Investigational Site 14244
Jacksonville, Florida, United States, 32256
Teva Investigational Site 14250
West Palm Beach, Florida, United States, 33407
Teva Investigational Site 14255
West Palm Beach, Florida, United States, 33409
United States, Georgia
Teva Investigational Site 14243
Atlanta, Georgia, United States, 30328
Teva Investigational Site 14258
Savannah, Georgia, United States, 31406
United States, Minnesota
Teva Investigational Site 14270
Minneapolis, Minnesota, United States, 55402
United States, Missouri
Teva Investigational Site 14256
Bridgeton, Missouri, United States, 63044-2513
United States, North Carolina
Teva Investigational Site 14248
Raleigh, North Carolina, United States, 27607
United States, Oklahoma
Teva Investigational Site 14363
Tulsa, Oklahoma, United States, 74136
United States, Texas
Teva Investigational Site 14273
Austin, Texas, United States, 78759
United States, Utah
Teva Investigational Site 14375
Salt Lake City, Utah, United States, 84109
Sponsors and Collaborators
Teva Branded Pharmaceutical Products R&D, Inc.
Investigators
Layout table for investigator information
Study Director: Teva Medical Expert, MD Teva Pharmaceuticals USA
Layout table for additonal information
Responsible Party: Teva Branded Pharmaceutical Products R&D, Inc.
ClinicalTrials.gov Identifier: NCT04530110    
Other Study ID Numbers: TV48125-CNS-30084
2019-002056-16 ( EudraCT Number )
First Posted: August 28, 2020    Key Record Dates
Last Update Posted: November 17, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be reviewed for scientific merit, product approval status, and conflicts of interest. Patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please email USMedInfo@tevapharm.com to make your request

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Teva Pharmaceutical Industries ( Teva Branded Pharmaceutical Products R&D, Inc. ):
episodic migraine
chronic migraine
Additional relevant MeSH terms:
Layout table for MeSH terms
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases